This strategic partnership brings together Nemera’s know-how in combination product device
development and industrialisation, with Therakind’s experience in developing and delivering
innovative medicines to patients.
The DriDose® platform – a dry powder intranasal device portfolio developed by Therakind –
perfectly complements Nemera’s existing range of nasal delivery solutions, which currently
supports liquid formulations. Nemera, a global leader in design, development and
manufacturing of drug delivery device solutions, broadens its innovative nasal portfolio to
include a complete dry powder delivery platform, further enhancing its end-to-end offering
for pharmaceutical and biotechnology partners.
Therakind, a UK-based pharmaceutical company with a strong track record in transitioning
products from development to regulatory approval is consolidating its core business of drug
device combination product development. Therakind will continue to leverage the DriDose®
platform to enhance patient outcomes both with internal projects and in collaboration with
third parties.
Dr Susan Conroy, CEO of Therakind said: “We are delighted to partner with Nemera, known
for its expertise in drug delivery solutions and novel device industrialisation. As a market leader
in devices with a global presence, Nemera is an ideal partner for the DriDose® portfolio
industrialisation and expansion.”
Dimitri Grasswill, Vice President of Nemera’s Ear, Nose and Throat business added: “We are
thrilled to partner with Therakind and benefit from their strong track record in pharmaceutical
development and regulatory approvals. The innovative DriDose® technology will open Nemera
to new therapeutic areas in nasal drug delivery and will significantly improve patients’ lives –
it perfectly complements our product portfolio especially by targeting unmet needs in systemic
and non-systemic treatments.”
Together, Nemera and Therakind will accelerate the development of next generation nasal
therapies, offering pharmaceutical partners expanded formulation expertise and innovative,
patient friendly devices.
About Nemera
Nemera is a world-leading provider of drug delivery device solutions and combination product
services. Our mission of putting patients first drives us to design and manufacture devices that
maximize treatment efficacy. From early device strategy to state-of-the-art manufacturing, we
are committed to delivering the highest quality standards to our customers.
Contact Nemera
Coraline Cortot
Global Communications Manager
+33 6 18 78 27 74 I coraline.cortot@nemera.net
For more information, visit:
www.nemera.net
https://www.linkedin.com/company/nemera/
https://www.instagram.com/nemeratalent/
About Therakind
Therakind is a specialty UK-based pharmaceutical company dedicated to improving patient
compliance. This is achieved by focusing on improving drug delivery and patient acceptability
through innovative formulations and delivery technologies. Therakind is advancing a pipeline
of novel drug-device combinations and new treatment approaches with its own products and
those of its partners.
For more information, please contact:
www.therakind.com
Tel: +44 (0) 20 8346 6035
Email: bd@therakind.com
